A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-Cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK 618334 in Healthy Male Volunteers.

Trial Profile

A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-Cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK 618334 in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs GSK 618334 (Primary)
  • Indications Impulse control disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Oct 2008 Actual start date changed from May 2007 to Jun 2007 as reported by Clinicaltrials.gov.
    • 18 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top